Tags

Type your tag names separated by a space and hit enter

Neuroimaging and analytical methods for studying the pathways from mild cognitive impairment to Alzheimer's disease: protocol for a rapid systematic review.
Syst Rev. 2020 04 02; 9(1):71.SR

Abstract

BACKGROUND

Alzheimer's disease (AD) is a neurodegenerative disorder commonly associated with deficits of cognition and changes in behavior. Mild cognitive impairment (MCI) is the prodromal stage of AD that is defined by slight cognitive decline. Not all with MCI progress to AD dementia. Thus, the accurate prediction of progression to Alzheimer's, particularly in the stage of MCI could potentially offer developing treatments to delay or prevent the transition process. The objective of the present study is to investigate the most recent neuroimaging procedures in the domain of prediction of transition from MCI to AD dementia for clinical applications and to systematically discuss the machine learning techniques used for the prediction of MCI conversion.

METHODS

Electronic databases including PubMed, SCOPUS, and Web of Science will be searched from January 1, 2017, to the date of search commencement to provide a rapid review of the most recent studies that have investigated the prediction of conversion from MCI to Alzheimer's using neuroimaging modalities in randomized trial or observational studies. Two reviewers will screen full texts of included papers using predefined eligibility criteria. Studies will be included if addressed research on AD dementia and MCI, explained the results in a way that would be able to report the performance measures such as the accuracy, sensitivity, and specificity. Only studies addressed Alzheimer's type of dementia and its early-stage MCI using neuroimaging modalities will be included. We will exclude other forms of dementia such as vascular dementia, frontotemporal dementia, and Parkinson's disease. The risk of bias in individual studies will be appraised using an appropriate tool. If feasible, we will conduct a random effects meta-analysis. Sensitivity analyses will be conducted to explore the potential sources of heterogeneity.

DISCUSSION

The information gathered in our study will establish the extent of the evidence underlying the prediction of conversion to AD dementia from its early stage and will provide a rigorous and updated synthesis of neuroimaging modalities allied with the data analysis techniques used to measure the brain changes during the conversion process.

SYSTEMATIC REVIEW REGISTRATION

PROSPERO,CRD42019133402.

Links

PMC Free PDF

Authors+Show Affiliations

Ahmadzadeh M
Digital Health Hub, Simon Fraser University, 4190 Galleria 4, 250 - 13450 102 Ave, Surrey, BC, V3T 0A3, Canada. School of Interactive Arts and Technology, Simon Fraser University, 250 - 13450 102 Ave, Surrey, BC, V3T 0A3, Canada. Science and Technology for Aging Research Institute, Simon Fraser University, 250 - 13450 102 Ave, Surrey, BC, V3T 0A3, Canada.
Christie GJ
Digital Health Hub, Simon Fraser University, 4190 Galleria 4, 250 - 13450 102 Ave, Surrey, BC, V3T 0A3, Canada. School of Interactive Arts and Technology, Simon Fraser University, 250 - 13450 102 Ave, Surrey, BC, V3T 0A3, Canada. Science and Technology for Aging Research Institute, Simon Fraser University, 250 - 13450 102 Ave, Surrey, BC, V3T 0A3, Canada.
Cosco TD
Gerontology Research Center, Simon Fraser University, 2800-515 West Hastings St, Vancouver, V6B 5 K3, Canada. Oxford Institute of Population Ageing, University of Oxford, 66 Banbury Road, Oxford, OX2 6PR, UK.
Moreno S
Digital Health Hub, Simon Fraser University, 4190 Galleria 4, 250 - 13450 102 Ave, Surrey, BC, V3T 0A3, Canada. sylvain_moreno@sfu.ca. School of Interactive Arts and Technology, Simon Fraser University, 250 - 13450 102 Ave, Surrey, BC, V3T 0A3, Canada. sylvain_moreno@sfu.ca. Science and Technology for Aging Research Institute, Simon Fraser University, 250 - 13450 102 Ave, Surrey, BC, V3T 0A3, Canada. sylvain_moreno@sfu.ca.

MeSH

Alzheimer DiseaseBrainCognitionCognitive DysfunctionDisease ProgressionHumansMeta-Analysis as TopicNeuroimagingSystematic Reviews as Topic

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32241302

Citation

Ahmadzadeh, Maryam, et al. "Neuroimaging and Analytical Methods for Studying the Pathways From Mild Cognitive Impairment to Alzheimer's Disease: Protocol for a Rapid Systematic Review." Systematic Reviews, vol. 9, no. 1, 2020, p. 71.
Ahmadzadeh M, Christie GJ, Cosco TD, et al. Neuroimaging and analytical methods for studying the pathways from mild cognitive impairment to Alzheimer's disease: protocol for a rapid systematic review. Syst Rev. 2020;9(1):71.
Ahmadzadeh, M., Christie, G. J., Cosco, T. D., & Moreno, S. (2020). Neuroimaging and analytical methods for studying the pathways from mild cognitive impairment to Alzheimer's disease: protocol for a rapid systematic review. Systematic Reviews, 9(1), 71. https://doi.org/10.1186/s13643-020-01332-7
Ahmadzadeh M, et al. Neuroimaging and Analytical Methods for Studying the Pathways From Mild Cognitive Impairment to Alzheimer's Disease: Protocol for a Rapid Systematic Review. Syst Rev. 2020 04 2;9(1):71. PubMed PMID: 32241302.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuroimaging and analytical methods for studying the pathways from mild cognitive impairment to Alzheimer's disease: protocol for a rapid systematic review. AU - Ahmadzadeh,Maryam, AU - Christie,Gregory J, AU - Cosco,Theodore D, AU - Moreno,Sylvain, Y1 - 2020/04/02/ PY - 2019/08/28/received PY - 2020/03/15/accepted PY - 2020/4/4/entrez PY - 2020/4/4/pubmed PY - 2021/6/25/medline KW - Alzheimer KW - Conversion KW - Data analysis KW - Machine learning KW - Mild cognitive impairment KW - Modality KW - Neuroimaging KW - Prediction KW - Systematic review SP - 71 EP - 71 JF - Systematic reviews JO - Syst Rev VL - 9 IS - 1 N2 - BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder commonly associated with deficits of cognition and changes in behavior. Mild cognitive impairment (MCI) is the prodromal stage of AD that is defined by slight cognitive decline. Not all with MCI progress to AD dementia. Thus, the accurate prediction of progression to Alzheimer's, particularly in the stage of MCI could potentially offer developing treatments to delay or prevent the transition process. The objective of the present study is to investigate the most recent neuroimaging procedures in the domain of prediction of transition from MCI to AD dementia for clinical applications and to systematically discuss the machine learning techniques used for the prediction of MCI conversion. METHODS: Electronic databases including PubMed, SCOPUS, and Web of Science will be searched from January 1, 2017, to the date of search commencement to provide a rapid review of the most recent studies that have investigated the prediction of conversion from MCI to Alzheimer's using neuroimaging modalities in randomized trial or observational studies. Two reviewers will screen full texts of included papers using predefined eligibility criteria. Studies will be included if addressed research on AD dementia and MCI, explained the results in a way that would be able to report the performance measures such as the accuracy, sensitivity, and specificity. Only studies addressed Alzheimer's type of dementia and its early-stage MCI using neuroimaging modalities will be included. We will exclude other forms of dementia such as vascular dementia, frontotemporal dementia, and Parkinson's disease. The risk of bias in individual studies will be appraised using an appropriate tool. If feasible, we will conduct a random effects meta-analysis. Sensitivity analyses will be conducted to explore the potential sources of heterogeneity. DISCUSSION: The information gathered in our study will establish the extent of the evidence underlying the prediction of conversion to AD dementia from its early stage and will provide a rigorous and updated synthesis of neuroimaging modalities allied with the data analysis techniques used to measure the brain changes during the conversion process. SYSTEMATIC REVIEW REGISTRATION: PROSPERO,CRD42019133402. SN - 2046-4053 UR - https://www.unboundmedicine.com/medline/citation/32241302/Neuroimaging_and_analytical_methods_for_studying_the_pathways_from_mild_cognitive_impairment_to_Alzheimer's_disease:_protocol_for_a_rapid_systematic_review_ DB - PRIME DP - Unbound Medicine ER -